Discuss MannKind Corp.
MannKind Corp.
WKN: A2DMZL / Symbol: MNKD / Name: MannKind / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
3,36 €
-0,41 %
MannKind (MNKD) had its price target lowered by Wedbush from $10.00 to $8.00. They now have an "outperform" rating on the stock.
Ratings data for MNKD provided by MarketBeat
MannKind (MNKD) was given a new $8.00 price target by Mizuho. They now have an "outperform" rating on the stock.
Ratings data for MNKD provided by MarketBeat
MannKind (MNKD) had its price target raised by Wells Fargo & Company from $7.00 to $8.00. They now have an "overweight" rating on the stock.
Ratings data for MNKD provided by MarketBeat
MannKind (MNKD) had its price target lowered by Mizuho from $8.00 to $7.00. They now have an "outperform" rating on the stock.
Ratings data for MNKD provided by MarketBeat
MannKind (MNKD) had its price target raised by HC Wainwright from $8.00 to $10.00. They now have a "buy" rating on the stock.
Ratings data for MNKD provided by MarketBeat
MannKind (MNKD) had its "overweight" rating reaffirmed by Wells Fargo & Company.
Ratings data for MNKD provided by MarketBeat
MannKind (MNKD) had its "buy" rating reaffirmed by HC Wainwright.
Ratings data for MNKD provided by MarketBeat
MannKind (MNKD) had its "overweight" rating reaffirmed by Wells Fargo & Company.
Ratings data for MNKD provided by MarketBeat
Neueste Beiträge
B__Riley_Financial__ in Anika Therapeutics diskutieren